DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Wells - 2 Larry Biegelsen - 2 Biegelsen - 2 John Rainey - 1 Eli Lilly's Mounjaro - 1 Eli Lilly - 1 Morgan Stanley - 1 Daniel Lyons - 1
Top related locs:
U.S GLP EU Japan
Top related orgs:
Wall Street - 1 Nordisk's Wegovy - 1 Bank of - 1 Walmart - 1 Health - 1 Novo Nordisk - 1 Medicare - 1 Drug - 1

Search resuls for: "Biegelsen"


5 mentions found


☆ Will weight loss drugs lead to less food consumption? Here's what Walmart is saying
  + stars: | 2023-09-27 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +5 min
While there has been a huge gain, it is barely scratching the surface of the potential market. Some potential patients don't have coverage of the pricey medicines through their health insurance plans yet. (For example, those seeking to use GLP-1 drugs for obesity can't receive coverage if they are insured by Medicare as the federal health plan is not allowed to cover weight loss drugs.) Walmart told Bank of America that fiscal second-quarter sales benefited roughly 1% from GLP-1 drug sales volumes. Its stock has fallen 45% year to date on fears that these drugs will shrink the company's market potential.
Persons: John Rainey, Eli Lilly's Mounjaro, Eli Lilly, Morgan Stanley, Wells, Larry Biegelsen, Biegelsen, Daniel Lyons, Janus Henderson, Lyons, — CNBC's Michael Bloom Organizations: Wall Street, Nordisk's Wegovy, Bank of, Walmart, Health, Novo Nordisk, Medicare, Drug, Bank of America, Janus, Janus Henderson Investors, CNBC Locations: U.S, GLP
☆ GE HealthCare can surge more than 25% as it capitalizes on key Alzheimer's opportunity, Wells Fargo says
  + stars: | 2023-08-16 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
Wells Fargo is confident GE HealthCare can benefit from the growth of a key Alzheimer's drug. The firm initiated coverage of the medical device provider with an overweight rating and a $90 per share price target. Analyst Larry Biegelsen highlighted the growth of Alzheimer's drug Leqembi as a potential growth driver for GE HealthCare, given that the treatment requires four MRI scans throughout the process. Shares of GE HealthCare have gained more than 20% this year. GEHC YTD mountain GE HealthCare year to date — CNBC's Michael Bloom contributed to this report.
Persons: Wells, Larry Biegelsen, Leqembi, Biegelsen, Michael Bloom Organizations: GE, GE HealthCare, Food and Drug Administration Locations: EU, Japan
☆ This biotech stock could yield 33% upside ahead of cancer trial data, Wells Fargo says
  + stars: | 2023-05-16 | by ( Brian Evans | ) www.cnbc.com   time to read: +2 min
Wells Fargo expects upcoming results from Novocure's LUNAR trial to be a catalyst for the stock. Novocure shares were gaining 3.5% on the back of the Wells Fargo upgrade, which lifted the stock's rating to overweight from equal weight. Analyst Larry Biegelsen also set a new price target of $104 per share, which represents 33% upside from Monday's closing price of $78.38. The LUNAR trial studied the efficacy of combining tumor treating fields, which target tumors with electrical frequencies, with more traditional therapies, including immunotherapies, to treat non-small cell lung cancer. NVCR YTD mountain Novocure stock could yield as much as 33% upside ahead of cancer treatment study data, Wells Fargo says.
☆ Wells Fargo upgrades this medical device maker, cites improving industry trends
  + stars: | 2023-04-24 | by ( Samantha Subin | ) www.cnbc.com   time to read: +2 min
Analyst Larry Biegelsen upgraded the medical device maker to overweight from equal weight in a Sunday note, saying that shares should benefit from improving medtech trends and a "maturing" product pipeline. "We rate MDT Overweight as we believe that the company will benefit as underlying medtech markets improve as staffing shortages ease in major markets," he said. Within the company's product pipeline, Biegelsen sees the biggest potential upside from the U.S. Food and Drug Administration's approval of its upgraded insulin pump known as 780G. According to Biegelsen, Medtronic's valuation also looks attractive, trading at a sharp discount to peers. "We believe once MDT moves past its FY2024 guidance in May, the stock can re-rate on the overall medtech recovery and product pipeline," he wrote.
☆ Shares of new emphysema treatment maker could rally more than 40%, says Wells Fargo
  + stars: | 2023-02-27 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +1 min
Wells Fargo upgraded Pulmonx shares to overweight from equal weight on Monday, noting that the company is gaining traction after a challenging period during the Covid pandemic. Analyst Larry Biegelsen raised his price target to $15 from $10, implying a 44.6% upside from Friday's closing price. He added, "We were also encouraged by the increase in utilization at existing accounts and the growth in new accounts in Q4," the analyst wrote. Pulmonx recently received approval for its Zephyr valves in Japan, which Biegelsen anticipated could amount to roughly another $1 billion for the company. Pulmonx shares gained 8% on Monday following the upgrade.
0 next >>
Total: 5